A revolutionary way to treat type 2 diabetes
| Reference number | |
| Coordinator | ATROGI AB - Arrhenius laboratoriet |
| Funding from Vinnova | SEK 5 000 000 |
| Project duration | October 2017 - December 2019 |
| Status | Completed |
Important results from the project
The ultimate goal is a drug for the treatment of type 2 diabetes (T2D). One purpose with the project was to develop a candidate drug (CD) and to prepare for safety and clinical studies. A CD was nominated and larger amounts of material suitable for safety studies have been produced. Another purpose with the project has been to establish good contacts with pharmaceutical companies with an interest in type 2 diabetes. This has been successful and discussions are ongoing.
Expected long term effects
The candidate drug that was nominated in the project has fulfilled all requirements necessary to enter safety studies. The production of material for the safety studies has been successful. If the safety studies are successful the compound will enter clinical studies. The contacts that have been established with pharmaceutical companies with an interest in type 2 diabetes have led to further discussions
Approach and implementation
A candidate drug was nominated after an iterative process were compounds were designed, synthesized and analyzed. The original synthesis was modified and improved to be able to produce the large amounts of material needed for the safety studies. Detailed preparations of these studies have been made and contacts have been established with clinics able to conduct studies in man. In parallel, discussions with pharmaceutical companies are ongoing with an aim to establish a future collaboration.